Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nitrofurantoin
Drug ID BADD_D01576
Description Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.[L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein.[A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.[A179824] Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole].[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895]
Indications and Usage May be used as an alternative in the treatment of urinary tract infections. May be used by females pericoitally for prophylaxis against recurrent cystitis related to coitus.
Marketing Status Prescription; Discontinued
ATC Code J01XE01
DrugBank ID DB00698
KEGG ID D00439
MeSH ID D009582
PubChem ID 6604200
TTD Drug ID D0R0BX
NDC Product Code 62332-389; 0591-3686; 60687-472; 48087-0009; 61919-458; 43386-450; 16571-740; 63629-2464; 71205-365; 0591-3684; 60687-483; 13811-719; 40032-450; 0115-2024; 65162-689; 71335-1374; 48087-0148; 0591-3685; 51927-5024; 0472-1992; 62332-390; 68001-423; 62332-391; 71052-240; 46708-390; 48087-0029; 68071-5050; 70199-006; 46708-389; 71335-0878; 48087-0097; 48087-0081; 46708-391; 72189-179; 71205-370; 68071-2281; 70408-239; 48087-0147; 60862-006; 0115-2023; 48087-0146
Synonyms Nitrofurantoin | Furadoine | Nitrofurantoin, Monohydrate | Furantoin | Macrodantin | Nitrofurantoin Sodium Salt | Furadantin | Furadantine | Furadonine
Chemical Information
Molecular Formula C8H6N4O5
CAS Registry Number 67-20-9
SMILES C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.001035%
Drug hypersensitivity10.01.01.0010.003105%Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.0040.000405%
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Eczema23.03.04.006--
Electrolyte imbalance14.05.01.002--Not Available
Eosinophilia01.02.04.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
Feeling abnormal08.01.09.014--Not Available
Fibrosis08.03.01.001--Not Available
Flatulence07.01.04.002--
Fontanelle bulging17.02.05.006; 18.04.04.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glucose-6-phosphate dehydrogenase deficiency03.08.03.001; 01.06.05.001; 14.14.03.001--Not Available
Granulocytopenia01.02.03.003--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004--Not Available
Hepatitis chronic active09.01.07.006; 11.07.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.001035%
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.001035%
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice cholestatic09.01.01.005--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages